drug · antibody
durvalumab
pre_registrationupdated 3mo agoby $AZN ASTRAZENECA PLC🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 7Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 67 investigational indications.
indications
indications
NSCLC
targets
Programmed cell death 1 ligand 1
all catalysts(2)
Trials studying durvalumab
- phase2COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
- phase1A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
- phase3Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
- phase3A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- phase2A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
- phase3Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- phase3Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
- phase2Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
News(10)
- No deal between AstraZeneca and BMS, senior source insists: ReutersReuters has deflated rumors that AstraZeneca and Bristol Myers Squibb are discussing a possible merger, letting the air out of industry-wide speculation over what could have been the largest deal i…biospace · 6d ago
- As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca mergerWhile both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…biospace · 8d ago
- ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal everIf AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.biospace · 9d ago
- Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad ideaCombining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patien…fiercebiotech · 9d ago
- Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combinationAfter keeping tight-lipped for nearly two years, Merck & Co. briefly dropped the first concrete hint as to where it intends to take its PD-1xVEGF bispecific antibody—before quietly scrubbing the ev…fiercebiotech · 14d ago
- AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failureAstraZeneca remains "very much on track" to hit its 2030 goal of reaching $80 billion in revenue despite the recent late-stage failure of Wainua in ATTR-cardiomyopathy, CEO Pascal Soriot said durin…biospace · 16d ago
- Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readoutsWith a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.biospace · 21d ago
- AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions🔎 AstraZeneca narrows path for failed antibody: The company announced last summer that its monoclonal antibody anselamimab missed the primary endpoint in a pair of Phase 3 trials for patients with…endpoints · 2mo ago
- Allogene CEO to step down; Agios drug fails key testDavid Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.biopharma_dive · 2mo ago
- Durvalumab Plus BCG Reduces High-Risk NMIBC Recurrence or Death Risk by 32% in Phase 3 POTOMAC TrialDurvalumab plus BCG induction and maintenance yielded an HR of 0.68 vs BCG alone for DFS in BCG-naive, high-risk non–muscle-invasive bladder cancer.onclive · 2mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that